Meeting
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
Authors
Ilya Tsimafeyeu
Kidney Cancer Research Bureau, Moscow, Russia
Ilya Tsimafeyeu , Pavel Borisov , Ahmed Abdelgafur , Roman Leonenkov , Olga Novikova , Irina Guseva , Marina Demchenkova , Nadezhda Mikhailova , Andrey Semenov , Zakhar Yurmazov , Irina Sivunova , Madina Ramazanova , Sergey Gamayunov , Dmitry Kosov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02700568
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 666)
DOI
10.1200/JCO.2018.36.6_suppl.666
Abstract #
666
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.
First Author: Thomas Cosgriff
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
First Author: Antoine Thiery-Vuillemin